Surface markers of lymphocyte activation and markers of cell proliferation

Clinica Chimica Acta

Volumn 413, Issue 17-18, 2012, Pages 1338-1349

  Shipkova, Maria ^a   Wieland, Eberhard ^a  

^a KLINIKUM STUTTGART   (Germany)

Author keywords

Cell proliferation; Immunosuppressants; Mitogen stimulation; Pharmacodynamics; T cell activation; Transplantation

Indexed keywords

CD134 ANTIGEN; CD137 ANTIGEN; CD27 ANTIGEN; CD28 ANTIGEN; CD40 LIGAND; CD69 ANTIGEN; CD70 ANTIGEN; CD71 ANTIGEN; CD86 ANTIGEN; CYCLINE; CYCLOSPORIN; DIPEPTIDYL PEPTIDASE IV; EVEROLIMUS; FAS ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE ANTIGEN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; LYMPHOCYTE SURFACE MARKER; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATURAL KILLER CELL RECEPTOR NKG2D; OX40 LIGAND; PREDNISOLONE; RAPAMYCIN; TACROLIMUS;

ANTIGEN EXPRESSION; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; EX VIVO STUDY; GRAFT REJECTION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFECTION; INTRACELLULAR SIGNALING; KIDNEY GRAFT REJECTION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; CELL MEMBRANE; CELL PROLIFERATION; HUMANS; LYMPHOCYTES;

EID: 84862758824     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.11.006     Document Type: Review

References (84)

1. Waki K. UNOS Liver Registry: ten year survivals. Clin Transpl 2006, 29-39.
2. Kaneku H.K., Terasaki P.I. Thirty year trend in kidney transplants: UCLA and UNOS Renal Transplant Registry. Clin Transpl 2006, 1-27.
3. Srinivas T.R., Meier-Kriesche H.U. Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result. Clin J Am Soc Nephrol 2008, (Suppl. 2):S101-S116.
4. Meier-Kriesche H.U., Schold J.D., Srinivas T.R., Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004, 4:378-383.
5. Wieland E., Olbricht C.J., Süsal C., et al. Biomarkers as a tool for management of immunosuppression in transplant patients. Ther Drug Monit 2010, 32:560-572.
6. Bharat A., Mohanakumar T. Allopeptides and the alloimmune response. Cell Immunol 2007, 248:31-43.
7. El-Sawy T., Fahmy N.M., Fairchild R.L. Chemokines: directing leukocyte infiltration into allografts. Curr Opin Immunol 2002, 14:562-568.
8. Nankivell B.J., Alexander S.I. Rejection of the kidney allograft. N Engl J Med 2010, 363:1451-1462.
9. Barrett A.J., Rezvani K., Solomon S., et al. New developments in allotransplant immunology. Hematology Am Soc Hematol Educ Program 2003, 102:350-371.
10. Wucherpfennig K.W., Allen P.M., Celada F., et al. Polyspecificity of T cell and B cell receptor recognition. Semin Immunol 2007, 19:216-224.
11. Pasare C., Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Adv Exp Med Biol 2005, 560:11-18.
12. Kabelitz D. Expression and function of Toll-like receptors in T lymphocytes. Curr Opin Immunol 2007, 19:39-45.
13. Raedler H., Heeger P.S. Complement regulation of T-cell alloimmunity. Curr Opin Organ Transplant 2010, 16:54-60.
14. Suárez-Alvarez B., López-Vázquez A., Baltar J.M., Ortega F., López-Larrea C. Potential role of NKG2D and its ligands in organ transplantation: new target for immunointervention. Am J Transplant 2009, 9:251-257.
15. Yu G., Xu X., Vu M.D., Kilpatrick E.D., Li X.C. NK cells promote transplant tolerance by killing donor antigen-presenting cells. J Exp Med 2006, 203:1851-1858.
16. Clathworthy M.R. Targeting B cells and antibody in transplantation. Am J Transplant 2011, 11:1359-1367.
17. Csencsits K.L., Bishop D.K. Contrasting alloreactive CD4+ and CD8+ T cells: there's more to it than MHC restriction. Am J Transplant 2003, 3:107-115.
18. Häyry P. Molecular pathology of acute and chronic rejection. Transplant Proc 1994, 26:3280-3284.
19. Chatila T., Silverman L., Miller R., Geha R. Mechanisms of T cell activation by the calcium ionophore ionomycin. J Immunol 1989, 143:1283-1289.
20. Zarling J.M., McKeough M., Bach F.H. A sensitive micromethod for generating and assaying allogeneically induced cytotoxic human lymphocytes. Transplantation 1976, 21:468-476.
21. Trickett A., Kwan Y.L. T cell stimulation and expansion using anti-CD3/CD28 beads. J Immunol Methods 2003, 275:251-255.
22. Barten M.J., Gummert J.F., van Gelder T., Shorthouse R., Morris R.E. Flow cytometric quantitation of calcium-dependent and -independent mitogen-stimulation of T cell functions in whole blood: inhibition by immunosuppressive drugs in vitro. J Immunol Methods 2001, 253:95-112.
23. Leonardi E., Girlando S., Serio G., et al. PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variables. J Clin Pathol 1992, 45:416-419.
24. Palutke M., Tabaczka P.M., Kukuruga D.L., Kantor N.L. A method for measuring lymphocyte proliferation in mixed lymphocyte cultures using a nuclear proliferation antigen, Ki-67, and flow cytometry. Am J Clin Pathol 1989, 91:417-421.
25. Schlegel P.G. The role of adhesion and costimulation molecules in graft-versus-host disease. Acta Haematol 1997, 97:105-117.
26. Testi R., Phillips J.H., Lanier L.L. T cell activation via Leu-23 (CD69). J Immunol 1989, 143:1123-1128.
27. Hintzen R.Q., Lens S.M., Lammers K., Kuiper H., Beckmann M.P., van Lier R.A. Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation. J Immunol 1995, 154:2612-2623.
28. Schuurman H.J., van Wichen D., de Weger R.A. Expression of activation antigens on thymocytes in the 'common thymocyte' stage of differentiation. Thymus 1989, 14:43-53.
29. Miyawaki T., Uehara T., Nibu R., et al. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J Immunol 1992, 149:3753-3758.
30. Li X.C., Rothstein D.M., Sayegh M.H. Costimulatory pathways in transplantation: challenges and new developments. Immunol Rev 2009, 229:271-293.
31. Ohnuma K., Takahashi N., Yamochi T., Hosono O., Dang N.H., Morimoto C. Role of CD26/dipeptidyl peptidase IV in human T cell activation and function. Front Biosci 2008, 13:2299-2310.
32. + T cells during active, latent and resolved infection. Imunology 2009, 126:346-353.
33. Heemann U.W., Tullius S.G., Azuma H., Kupiec-Weglinsky J., Tilney N.L. Adhesion molecules and transplantation. Ann Surg 1994, 219:4-12.
34. Tan J., Zhou G. Chemokine receptors and transplantation. Cell Mol Immunol 2005, 2:343-349.
35. Qin S., Rottman J.B., Myers P., et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998, 101:746-754.
36. Holling T.M., Schooten E., van Den Elsen P.J. Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men. Hum Immunol 2004, 65:282-290.
37. Boleslawski E., Othman S.B., Aoudjehane L., et al. CD28 expression by peripheral blood lymphocytes as a potential predictor of the development of de novo malignancies in long-term survivors after liver transplantation. Liver Transpl 2011, 17:299-305.
38. Biselli R., Matricardi P.M., D'Amelio R., Fattorossi A. Multiparametric flow cytometric analysis of the kinetics of surface molecule expression after polyclonal activation of human peripheral blood T lymphocytes. Scand J Immunol 1992, 35:439-447.
39. Barten M.J., Streit F., Boeger M., et al. Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood. Transplantation 2004, 77:1154-1162.
40. Niwa M., Miwa Y., Kuzuya T., et al. Stimulation index for PCNA mRNA in peripheral blood as immune function monitoring after renal transplantation. Transplantation 2009, 87:1411-1414.
41. Böhler T., Waiser J., Budde K., et al. The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation. Transplant Proc 1998, 30:2195-2197.
42. Augustine N.H., Pasi B.M., Hill H.R. Comparison of ATP production in whole blood and lymphocyte proliferation in response to phytohemagglutinin. J Clin Lab Anal 2007, 21:265-270.
43. Wu J., Palladino M.A., Figari I.S., Morris R.E. Comparative immunoregulatory effects of rapamycin, FK 506 and cyclosporine on mitogen-induced cytokine production and lymphoproliferation. Transplant Proc. 1991, 23:238-240.
44. Shipkova M., Wieland E., Schütz E., et al. The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes. Transplant Proc 2001, 33:1080-1081.
45. Lyons A.B., Parish C.R. Determination of lymphocyte division by flow cytometry. J Immunol Methods 1994, 71:131-137.
46. Babel N., Reinke P., Volk H.D. Lymphocyte markers and predicition of long-term renal allograft acceptance. Curr Opin Nephrol Hypertens 2009, 18:489-494.
47. Böhler T., Nolting J., Kamar N., et al. Validation of immunological biomarkers for the pharmacodynamic monitoring of immunosuppressive drugs in humans. Ther Drug Monit 2007, 29:77-86.
48. Dambrin C., Klupp J., Morris R.E. Pharmacodynamics of immunosuppressive drugs. Curr Opin Immunol 2000, 12:557-562.
49. Kubbies M., Schindler D., Hoehn H., Rabinovitch P.S. Cell cycle kinetics by BrdU-Hoechst flow cytometry: an alternative to the differential metaphase labeling. Cell Tissue Kinet 1985, 18:551-562.
50. Shaw L.M., Annesley T.M., Kaplan B., Brayman K.L. Analytic requirements for immunosuppressive drugs in clinical trials. Ther Drug Monit 1995, 17:577-583.
51. Davis C., Wu X., Li W., Fan H., Reddy M. Stability of immunophenotypic markers in fixed peripheral blood for extended analysis using flow cytometry. J Immunol Methods 2011, 363:158-165.
52. Fletcher M.A., Baron G.C., Ashman M.R., Fischl M.A., Klimas N.G. Use of whole blood methods in assessment of immune parameters in immunodeficiency states. Diagn Clin Immunol 1987, 5:69-81.
53. Rainen L., Oelmueller U., Jurgensen S., et al. Stabilization of mRNA expression in whole blood samples. Clin Chem 2002, 48:1883-1890.
54. Wieland E., Shipkova M., Martius Y., et al. Association between pharmacodynamic biomarkers and clinical events in the early phase after kidney transplantation: a single-center pilot study. Ther Drug Monit 2011, 33:341-349.
55. Berry V., Magill A., Yost M., Janosky J., Sindhi R. Individualizing combination of two antiproliferative immunosuppressants with pharmacodynamic modeling of stimulated lymphocyte responses. Cytometry A 2006, 69:95-103.
56. Wang H., Grzywacz B., Sukovich D., et al. The unexpected effect of cyclosporin A on CD56+CD16- and CD56+CD16+ natural killer cell subpopulations. Blood 2007, 110:1530-1539.
57. Barten M.J., Dhein S., Chang H., et al. Assessment of immunosuppressive drug interactions: inhibition of lymphocyte function in peripheral human blood. J Immunol Methods 2003, 283:99-114.
58. Shipkova M., Krizan E., Klett C., Leicht S., Wieland E. Effect of immunosuppressants on CD26/dipetidyl peptidase IV expression on CD3 in vitro. Ther Drug Monit 2009, 31:660.
59. He X., Smeets R.L., Koenen H.J., et al. Mycophenolic acid-mediated suppression of human CD4+ T cells: more than mere guanine nucleotide deprivation. Am J Transplant 2011, 11:439-449.
60. Sindhi R., Allaert J., Gladding D., et al. Modeling individual variation in biomarker response to combination immunosuppression with stimulated lymphocyte responses-potential clinical implications. J Immunol Methods 2003, 272:257-272.
61. Van Rijen M.M., Metselaar H.J., Hommes M., Ijzermans J.N., Tilanus H.W., Kwekkeboom J. Mycophenolic acid is a potent inhibitor of the expression of tumour necrosis factor- and tumour necrosis factor-receptor superfamily costimulatory molecules. Immunology 2003, 109:109-116.
62. Stalder M., Bîrsan T., Holm B., Haririfar M., Scandling J., Morris R.E. Quantification of immunosuppression by flow cytometry in stable renal transplant recipients. Ther Drug Monit 2003, 25:22-27.
63. Prémaud A., Rousseau A., Johnson G., et al. Inibition of T-cell activation and proliferation by mycophenolic acid in patients awaiting liver transplantation: PK/PD relationships. Pharmacol Res 2011, 63:432-438.
64. Kamar N., Glander P., Nolting J., et al. Pharmacodynamic evaluation of the first dose of mycophenolate mofetil before kidney transplantation. Clin J Am Soc Nephrol 2009, 4:936-942.
65. Hutchinson P., Chadban S.J., Atkins R.C., Holdsworth S.R. Laboratory assessment of immune function in renal transplant patients. Nephrol Dial Transplant 2003, 18:983-989.
66. Böhler T., Canivet C., Galvani S., et al. Pharmacodynamic monitoring of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable kidney-allograft recipients. Int Immunopharmacol 2008, 8:769-773.
67. Weigel G., Griesmacher A., Karimi A., Zuckermann A.O., Grimm M., Mueller M.M. Effect of mycophenolate mofetil therapy on lymphocyte activation in heart transplant recipients. J Heart Lung Transplant 2001, 21:1074-1079.
68. Canivet C., Böhler T., Galvani S., et al. T-cell function in maintenance renal transplant patients receiving mycophenolate mofetil and steroids with or without tacrolimus. Transpl Proc 2008, 40:3422-3423.
69. Barten M.J., Rahmel A., Garbade J., et al. Pharmacodynamic monitoring of the conversion of cyclosporine to tacrolimus in heart and lung transplant recipients. Transplant Proc 2005, 37:4532-4534.
70. Barten M.J., Tarnok A., Garbade J., et al. Pharmacodynamics of T-cell function for monitoring immunosuppression. Cell Prolif 2007, 40:50-63.
71. Morteau O., Blundell S., Chakera A., et al. Renal transplant immunosuppression impairs natural killer cell function in vitro and in vivo. PLoS One 2010, 12(5):e13294.
72. Deng M.C., Erren M., Roeder N., et al. T-cell and monocyte subsets, inflammatory molecules, rejection, and hemodynamics early after cardiac transplantation. Transplantation 1998, 65:1255-1261.
73. Beik A.I., Morris A.G., Higgins R.M., Lam F.T. Serial flow cytometric analysis of T-cell surface markers can be useful in differential diagnosis of renal allograft dysfunction. Clin Transplant 1998, 12:24-29.
74. Chang D.M., Ding Y.A., Kuo S.Y., Chang M.L., Wei J. Cytokines and cell surface markers in prediction of cardiac allograft rejection. Immunol Invest 1996, 25:13-21.
75. Boleslawski E., Ben Othman S., Grabar S., et al. CD25, CD28 and CD38 expression in peripheral blood lymphocytes as a tool to predict acute rejection after liver transplantation. Clin Transplant 2008, 22:494-501.
76. Roberti I., Reisman L. Serial evaluation of cell surface markers for immune activation after acute renal allograft rejection by urine flow cytometry-correlation with clinical outcome. Transplantation 2001, 71:1317-1320.
77. Sindhi R., Magill A., Bentlejewski C., et al. Enhanced donor-specific alloreactivity occurs independently of immunosuppression in children with early liver rejection. Am J Transplant 2005, 5:96-102.
78. Sindhi R., Manavalan J.S., Magill A., Suciu-Foca N., Zeevi A. Reduced immunosuppression in pediatric liver-intestine transplant recipients with CD8+CD28- T-suppressor cells. Hum Immunol 2005, 66:252-257.
79. Ashokkumar C., Bentlejewski C., Sun Q., et al. Allospecific CD154+ B cells associate with intestine allograft rejection in children. Transplantation 2010, 90:1226-1231.
80. Ashokkumar C., Talukdar A., Sun Q., et al. Allospecific CD154+ T cells associate with rejection risk after pediatric liver transplantation. Am J Transplant 2009, 9:179-191.
81. Millán O., Benitez C., Guillén D., et al. Biomarkers of immunoregulatory status in stable liver transplant recipients undergoing weaning of immunosuppressive therapy. Clin Immunol 2010, 137:337-346.
82. Latek R., Fleener C., Lamian V., et al. Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation. Transplantation 2009, 87:926-933.
83. Newell K.A., Asare A., Kirk A.D., et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 2010, 120:1836-1847.
84. Sagoo P., Perucha E., Sawitzki B., et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 2010, 120:1848-1861.